Northwest Biotherapeutics announced that its CTO, Dr. Marnix Bosch, will present new scientific data on the survival benefits of their DCVax-L immunotherapy for glioblastoma at the 2026 British Neuro-Oncology Society meeting. The presentation will use propensity score matching analyses to assess patient outcomes. This follows the company's completion of a large Phase III trial and ongoing regulatory review in the UK. The data could impact the future approval and adoption of this personalized cancer treatment.
SupplySide Global 2026, a leading event for supplement, food, and beverage innovation, will be held October 28-30 in Las Vegas with education sessions from October 26-30. The event expands to three expo days, offering attendees more time to connect w...
Pizza Hut UK has reopened its iconic Marble Arch restaurant after a full refurbishment, celebrating its heritage since 1973. To mark the occasion, the brand launched a social media contest inviting customers to share photos of their Pizza Hut memorie...
GraniteShares has declared monthly distributions for its eight Autocallable ETFs, including ANV, TLA, MSR, ATC, PLA, AHD, SCA, and MRA. These ETFs offer distribution rates ranging from 0% to nearly 48%, reflecting their investment in single-stock aut...
Hostinger has introduced Hostinger Ecommerce, an AI-driven platform that allows small sellers to create product pages and checkout links from photos in minutes, without needing a website. The platform manages inventory, orders, payments, and shipping...
Hyperscale Data has purchased an additional 67 Bitcoin, increasing its total holdings to approximately 849 BTC. This aggressive accumulation strategy has pushed the combined value of its Bitcoin, cash, and silver assets to about $106.7 million, surpa...
